← Back to Search

Physical Therapy + Medication for Parkinson's Disease (TAME-PD Trial)

Phase < 1
Recruiting
Led By Shnehal Patel
Research Sponsored by Hubert Fernandez
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Punctuation of 5 in Hoehn and Yard modified scale: 'Wheelchair bound or bedridden unless aided'.
Presence of signs and symptoms suggestive of atypical parkinsonism
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare physical therapy alone to physical therapy plus medication (either low dose methylphenidate or atomoxetine) to see if the addition of medication leads to more improvement in gait and balance in patients with Parkinson disease.

Who is the study for?
This trial is for Parkinson's disease patients with significant gait and balance issues, despite stable dopaminergic therapy. They must score ≥2 on the UPDRS item for walking impairment. Exclusions include severe mental health issues, epilepsy, heart problems, glaucoma, liver disease, allergies to study drugs, wheelchair dependence or bedridden state without help.
What is being tested?
The TAME-PD trial is testing if adding low doses of either methylphenidate or atomoxetine to physical therapy can improve gait and balance in Parkinson's patients more than physical therapy alone. It's a pilot study where participants are randomly assigned to one of two groups in a blinded fashion.
What are the potential side effects?
Potential side effects from methylphenidate may include nervousness, trouble sleeping and increased blood pressure. Atomoxetine might cause dry mouth, nausea or fatigue. Physical therapy generally has minimal risks but could sometimes result in muscle soreness.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I need help to move from a wheelchair or bed.
Select...
I show signs of unusual Parkinson-like symptoms.
Select...
I don't have severe mental health issues, epilepsy, hyperthyroidism, glaucoma, irregular heartbeat, Tourette syndrome, liver disease, or allergies to specific ADHD medications.
Select...
I cannot undergo physical therapy due to health reasons.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Balance Evaluation
Secondary study objectives
Change in gait
Other study objectives
Motor function

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Active Control
Group I: Physical TherapyActive Control1 Intervention
Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
Group II: Physical Therapy plus MethylphenidateActive Control2 Interventions
Methylphenidate 20 mg daily in combination with PT
Group III: Physical Therapy plus AtomoxetineActive Control2 Interventions
Atomoxetine 10 mg daily in combination with PT or PT alone.

Find a Location

Who is running the clinical trial?

Hubert FernandezLead Sponsor
Shnehal PatelPrincipal InvestigatorThe Cleveland Clinic

Media Library

Physical Therapy Clinical Trial Eligibility Overview. Trial Name: NCT02879136 — Phase < 1
Parkinson's Disease Research Study Groups: Physical Therapy, Physical Therapy plus Methylphenidate, Physical Therapy plus Atomoxetine
Parkinson's Disease Clinical Trial 2023: Physical Therapy Highlights & Side Effects. Trial Name: NCT02879136 — Phase < 1
Physical Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT02879136 — Phase < 1
~4 spots leftby Dec 2025